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ABSTRACT 
Drug-eluting stents (DES) are considered the treatment of choice for most patients with obstructive coronary 
artery disease when percutaneous intervention (PCI) is feasible. However, stent thrombosis seems to occur more 
frequently with DES and occasionally is associated with resistance to anti-platelet drugs. We have experienced a 
case of recurrent stent thrombosis in a patient with clopidogrel resistance. A 63-year-old female patient suffered 
from acute myocardial infarction and underwent successful PCI of the left anterior descending coronary artery 
(LAD) with two DESs. She was found to be hyporesponsive to clopidogrel and was treated with triple anti-
platelet therapy (aspirin 100 mg, clopidogrel 75 mg, and cilostazol 200 mg daily). Three days after discharge, she 
developed chest pain and was again taken to the cardiac catheterization laboratory, where coronary angiography 
(CAG) showed total occlusion of the mid-LAD where the stent had been placed. After intravenous administra-
tion of a glycoprotein IIb/IIIa inhibitor, balloon angioplasty was performed, resulting in Thrombolysis In Myo-
cardial Infarction (TIMI) III antegrade flow. The next day, however, she complained of severe chest pain, and the 
electrocardiogram showed marked ST-segment elevation in V1-V6, I, and aVL with complete right bundle 
branch block. Emergent CAG revealed total occlusion of the proximal LAD due to stent thrombosis. She was 
successfully treated with balloon angioplasty and was discharged with triple anti-platelet therapy. (Korean Circ J 
2009;39:434-438) 
 





In recent years, drug-eluting stents (DES) have been 
demonstrated to dramatically reduce the rate of reste-
nosis and the need for repeat revascularization.
1-3) De-
spite these promising results, stent thrombosis seems to 
occur more frequently with DES and often seems to be 
associated with clopidogrel resistance.
4) We report a 
case of recurrent stent thrombosis associated with clo-
pidogrel resistance in a patient with acute myocardial 
infarction. 
A 63-year-old female was transferred to the Emergency 
Department complaining of squeezing chest pain that 
had increased over the past twelve hours. The electrocar-
diogram (ECG) showed ST-segment elevation in V1-V3 
(Fig. 1). She underwent emergent coronary angiography 
(CAG), which revealed critical stenosis in the proximal 
and middle left anterior descending coronary artery 
(LAD). She was successfully treated with two paclitaxel-
eluting stents (3.0×12 mm and 2.5×28 mm Taxus 
stents, Boston Scientific, Reading, PA, USA) in the pro-
ximal and middle LAD (Fig. 2). She was treated with tri-
ple antiplatelet therapy (aspirin 100 mg, clopidogrel 75 mg, 
and cilostazol 200mg daily) because she was found to be 
hyporesponsive to clopidogrel when tested for adenosine 
diphosphase (ADP)-induced platelet aggregation utiliz-
ing the VerifyNow P2Y12 point-of-care assay (181/0 
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P2Y12 reaction unit/%). 
Three days after discharge, she again developed chest 
pain and presented to the emergency department with 
mental confusion associated with acute pulmonary ede-
ma. The ECG showed ST-segment elevation in V1-V5 
(Fig. 3) and the cardiac enzymes were elevated (creatine   
kinase-MB 34.0 U/L, Troponin-I 67.01 ng/mL, Tropo-
nin-T 5.5 ng/mL). Emergency CAG, after intubation 
due to hypoxemia, showed total occlusion of the mid-
LAD due to stent thrombosis (Fig. 4). After intravenous 
administration of a glycoprotein IIb/IIIa receptor blocker 
(ReoPro
®), balloon angioplasty was carried out multiple 
times using a 3.0 mm balloon at 10-12 atm because of 
recurrent, immediate thrombus formation and coronary 
occlusion. The next day, however, she complained of 
severe chest pain again, and the ECG showed marked 
ST-segment elevation in V1-V6, I, and aVL; and new-
onset complete right bundle branch block with left an-
terior fascicular block (Fig. 5). Emergent CAG revealed 
thrombotic total occlusion of the proximal LAD (Fig. 6). 
She was successfully treated with balloon angioplasty 
and a final angiogram revealed improved flow over stent-
ed LAD without intraluminal filling defect. Despite the 
cilostazol medication, ADP-induced platelet aggregation 
Fig. 1. The electrocardiogram showed ST-segment elevation in V1-V3.
A  B
Fig. 2. A: coronary angiogram revealed critical stenosis in the proximal and middle left anterior descending coronary artery (LAD) (arrows).
B: two paclitaxel-eluting stents (3.0×12 mm and 2.5×28 mm Taxus stents, Boston Scientific, Reading, PA, USA) were successfully placed
in the occluded LAD.  
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showed that she was still hyporesponsive to clopidogrel 
(171/0 P2Y12 reaction unit/%). She was discharged af-
ter uneventful recovery with triple anti-platelet therapy 
using an increased dose of aspirin (aspirin 200 mg, clo-
pidogrel 75 mg, cilostazol 200 mg daily). The patient has 





We report this case to draw more attention to stent 
thrombosis associated with clopidogrel resistance after 
DES implantation. This case shows that a DES patient 
with clopidogrel resistance can be vulnerable to stent 
thrombosis even if treated with triple anti-platelet thera-
py, which in recent studies has been shown to be more 
effective in preventing stent thrombosis than conven-
tional dual anti-platelet therapy. Recently, there have been 
safety concerns with DES due to late stent thrombosis. 
Stent thrombosis is an uncommon but serious complica-
tion of coronary artery stents that often presents as myo-
cardial infarction (MI) or death. Over several trials, the 
incidence of stent thrombosis was 0.58-1.3% in DES.
5)6) 
Several factors have been associated with stent throm-
bosis, including older age, black race, diabetes mellitus, 
bifurcation lesion, in-stent restenosis lesion, procedure-
related factors such as stent malposition, greater stent 
length, postprocedure acute renal failure, non-compli-
ance to anti-platelet agent and anti-platelet resistance.
7-9) 
Anti-platelet resistance as an independent predictor of 
stent thrombosis, even several years after implantation 
of DES, increases the risk of stent thrombosis. In this 
Fig. 3. The electrocardiogram showed newly developed ST-segment elevation in V1-V5.
A  B
Fig. 4. A: emergent coronary angiogram showed near-total occlusion of the mid- left anterior descending coronary artery (LAD) due to stent
thrombosis (arrow). Balloon angioplasty was carried out multiple times using a 3.0 mm balloon at 10-12 atm with the aid of platelet glyco-
protein IIb/IIIa inhibitor. B: a final coronary angiogram showed Thrombolysis In Myocardial Infarction (TIMI) III antegrade flow with some
remaining filling defects in the LAD.  
 
Sung Soo Kim, et al.·437 
patient, stent thrombosis may have been caused by sev-
eral risk factors, especially anti-platelet resistance. 
The treatment of anti-platelet resistance is as yet un-
defined. Several therapeutic approaches (the addition of 
cilostazol or a glycoprotein IIb/IIIa inhibitor, increased 
dosage of clopidogrel and aspirin) might be taken for a 
patient with anti-platelet resistance. In our patient, al-
though cilostazol (200 mg daily) was added to conven-
tional dual anti-platelet therapy, recurrent stent throm-
bosis occurred. Subsequently, the daily dose of aspirin 
was increased from 100 mg to 200 mg.   
In the DES era, stent thrombosis is a fatal complica-
tion and anti-platelet therapy has been shown to be very 
important in preventing stent thrombosis. Thus, assess-
ment of the patient’s responsiveness to anti-platelet 
agents may be a crucial factor in monitoring these drugs’ 
therapeutic efficacy and improving clinical outcomes af-
ter implantation of DES. Recent studies have shown 
that adequate anti-platelet effects are not achieved in 
5% to 45% of the patients taking aspirin and in 4% to 
30% of patients taking clopidogrel
10)11) and therefore 
suggest that many patients are resistant or only partially 
responsive to the anti-platelet agents. Currently, however, 
routine screening for anti-platelet resistance remains a 
persistent, unresolved issue and further evidence is neces-
sary before it will be possible to recommend this testing 
as part of standard assessment of PCI candidates. In addi-
tion, further prospective studies are needed to set guide-
lines for optimal treatment of patients with antiplatelet 
resistance who are at increased risk of stent thrombosis, 
a catastrophic complication of DES implantation. 
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